Journals / Türk Hijyen ve Deneysel Biyoloji Dergisi / 2018 / Cilt: 75 - Sayı: 3

Drugs subject to special storage conditions or cold chain and evaluation in terms of applications

Özel saklama koşulu gerektiren veya soğuk zincire tabi ilaçlar ve uygulamalar açısından değerlendirmeler

Pages
305–322
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Following this, international regulations and guidelines on cold chain management and cold chain applications in Turkey have been included.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cold chain; is a special storage condition applied in the storage, transportation and distribution, which ensures that the temperature-sensitive medicinal product remains within the approved temperature ranges prescribed by the registration holder from the raw material stage to the packaged final product until reaching the user.
📊
Key Findings & Data:Products subject to cold chain application can be classified as; immunomodulators, monoclonal antibodies, hormones, enzymes, growth factors, plasminogen activators, coagulation factors, immunological products.
💡
Conclusion & Impact:Following this, international regulations and guidelines on cold chain management and cold chain applications in Turkey have been included.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cold chain; is a special storage condition applied in the storage, transportation and distribution, which ensures that the temperature-sensitive medicinal product remains within the approved temperature ranges prescribed by the registration holder from the raw material stage to the packaged final product until reaching the user. Products subject to cold chain application can be classified as; immunomodulators, monoclonal antibodies, hormones, enzymes, growth factors, plasminogen activators, coagulation factors, immunological products. Cold chain applications determined by the authorities need to be supplied at every stage ranging from the industrial production, distribution and administration of biopharmaceutical products. While the application of products in case of cold chain breakage poses a risk to the patient health, the disruption of these products causes pecuniary damage to the country economy because of the use of expensive raw materials and methods in the production of these products. In this review, the cold chain conditions applied to biotechnological and biological products to avoid the loss of activity and to provide stability at every stage during transport, storage and distribution have been extensively assessed. Unlike synthetic drugs, biopharmaceutical products were found to require cold chain application due to protein instability. In addition, the degradation pathways of proteins, the basic structure of biopharmaceutical products, and the effect of degradation causing conditions on preparations were examined and the effect of exposure to freezing and exposure to temperature on protein stability was evaluated. In this context, cold chain applications have been evaluated with the examples given for transport and storage conditions of the vaccines. Following this, international regulations and guidelines on cold chain management and cold chain applications in Turkey have been included.

Özet

Soğuk zincir; sıcaklığa hassas bir tıbbi ürününhammadde aşamasından ambalajlı nihai ürünedönüşüp kullanıcıya ulaşıncaya kadar geçen sürederuhsat sahibinin öngördüğü onaylanmış sıcaklıkaralıkları içerisinde kalmasını sağlayan, depolama,taşıma ve dağıtımında uygulanan özel saklamakoşuludur. Soğuk zincir uygulamasına tâbi ürünler;immünomodülatörler, monoklonal antikorlar,hormonlar, enzimler, büyüme faktörleri, plazminojenaktivatörleri, koagülasyon faktörleri ve immünolojikürünler şeklinde sınıflandırılabilir. Soğuk zinciruygulamalarının biyofarmasötik ürünün endüstrideüretiminden, dağıtımına ve uygulanmasına kadar heraşamasında sağlanması gerekmektedir. Soğuk zincirkırılması durumunda ürünlerin uygulanması hastasağlığı için risk oluştururken, bu ürünlerin bozularakatılması, üretiminde kullanılan hammaddelerinve yöntemlerin maliyetli olması nedeniyle ülkeekonomisine zarar vermektedir. Biyofarmasötikürünlerin, yapısında yer alan protein(lerin) kararsızlığınedeniyle soğuk zincir uygulamasına ihtiyaç duyduğusaptanmıştır. Bu derlemede; biyolojik ve biyoteknolojikürünlerin taşınması, saklanması ve dağıtımı sırasındaaktivite kaybı yaşanmaması ve ürün kalitesininher aşamada stabil kalması için uygulanan soğukzincir koşulları kapsamlı olarak değerlendirilmiştir.Ayrıca, biyofarmasötik ürünlerin temel yapısı olanproteinlerin degredasyon yolları ve degredasyonaneden olma koşullarının preparatlar üzerindekietkileri incelenmiş, donma ve sıcaklığa maruziyetinprotein stabilitesi üzerindeki etkisi değerlendirilmiştir.Bu kapsamda aşılardaki soğuk zincir uygulamaları,aşıların nakli ve saklanma koşulları açısından verilenörneklerle değerlendirilmiştir. Bunu takiben soğukzincir yönetimi ile ilgili uluslararası düzenlemeler,kılavuzlar ve Türkiye’deki soğuk zincir uygulamalarınayer verilmiştir.

🔖

Cite This Article

KÜÇÜKTÜRKMEN, B., BOZKIR, A. (2022). Drugs subject to special storage conditions or cold chain and evaluation in terms of applications. Türk Hijyen ve Deneysel Biyoloji Dergisi, Cilt: 75 - Sayı: 3, 305–322. https://ajindex.com/articles/624989

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Parenteral Drug Association Technical Report No. 39: Cold Chain Guidance for Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment. PDA Journal of Pharmaceutical Science and Technology, 2005; 59: 1-12
  2. Directive 2001/83/EC of the European Parliament and of The Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use. http://ec.europa.eu/ health//sites/health/files/files/eudralex/vol1/dir_2001_83_cons2009/2001_83_cons2009_ en.pdf Erişim tarihi: 01.07.2017
  3. Saka OM, Bozkır A. Eczacılıkta Yenilikler -2: Current and Future Approaches of Biomacromolecules: Formulation Design and Applications. Ankara University Faculty of Pharmacy Press No: 99, 2010; 117-42
  4. Bozkır A, Saka OM. Multiple Emulsions: Delivery System for Antigens. In: Aserin A, eds. Multiple Emulsion: Technology and Applications. New Jersey: John Wiley & sons Inc, 2008
  5. Saka OM, Bozkir A. Formulation and in vitro characterization of PEGylated chitosan and polyethylene imine polymers with thrombospondin-I gene bearing pDNA. J Biomed Mater Res B Appl Biomater, 2012; 100(4): 984-92
  6. Bozkır A, Saka OM. Chitosan-DNA nanoparticles: effect on DNA integrity, bacterial transformation and transfection efficiency. J Drug Target, 2004; 12(5):281-8
  7. Özbilgin N, Saka OM, Bozkır A. Preparation and In vitro In vivo Evaluation of Mucosal Adjuvant In situ Forming Gels With Diphtheria Toxoid. Drug delivery, 2013; 21(2): 140-147
  8. Bozkır A, Hayta G. Preparation and Evaluation of Multiple Emulsions water-in-oil-in-water (w/o/w) as Delivery System for Influenza Virus Antigens. J Drug Target, 2004, 12(3): 157-64
  9. Bozkır A, Hayta G, Saka OM. Comparison of biodegradable nanoparticles and multiple emulsions (water-in-oil-in-water) containing influenza virus antigen on the in vivo immune response in rats. Pharmazie, 2004, 59(9):723-5
  10. Rader RA. (Re)defining biopharmaceutical. Nature Biotechnology, 2008; 26(7): 743-51
  11. Groves JM. Pharmaceutical Technology, second edition, Taylor & Francis Group, 2006
  12. ICH Q5C: Stability testing of Biotechnological/ Biological products, Annex to the tripartite ICH guideline for stability of new drug substance and products, 1995. https://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/ Quality/Q5C/Step4/Q5C_Guideline.pdf Erişim tarihi: 01.07.2017
  13. Ratnaparkhi MP, Chaudhari SP, Pandya VA. Peptides and proteins in pharmaceuticals. Int